Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election ...

Biogen Inc. (NASDAQ:BIIB) also benefits from its strong pipeline, which shows promise in areas like lupus and Alzheimer’s ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...

Needham forecasts Biogen revenues to remain stable until 2025, rising ~3% by 2026. Biogen will face ongoing challenges as expectations for Leqembi need to adjusted to more realistic levels.

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

"potentially lowering patient burden and offering improved tolerability," according to Biogen. IgAN is a leading cause of kidney failure, affecting around 130,000 people in the US and another ...